OLIPASS CORPORATION Logo

OLIPASS CORPORATION

An R&D company developing RNA therapeutics using its proprietary OPNA platform.

244460 | KO

Overview

Corporate Details

ISIN(s):
KR7244460002
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시

Description

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-03-14 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 80.3 KB
2024-03-13 00:00
주주총회소집공고
Korean 123.3 KB
2024-03-13 00:00
의결권대리행사권유참고서류
Korean 124.4 KB
2024-03-13 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 33.5 KB
2024-03-12 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 78.6 KB
2024-03-12 00:00
증권발행결과(자율공시) (제11회차 CB)
Korean 7.3 KB
2024-03-12 00:00
내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Korean 17.3 KB
2024-03-12 00:00
기타시장안내(관리종목지정우려종목)
Korean 3.4 KB
2024-03-12 00:00
주주총회소집결의
Korean 9.4 KB
2024-03-11 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 76.7 KB
2024-03-11 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2024-03-06 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 96.0 KB
2024-03-06 00:00
주요사항보고서(전환사채권발행결정)
Korean 37.9 KB
2024-03-05 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 45.8 KB
2024-02-27 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 43.1 KB

Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OLIPASS CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.